Alvotech SA
NASDAQ:ALVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Country Average (24.3), the stock would be worth $3.07 (11% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 27.5 | $3.46 |
0%
|
| Country Average | 24.3 | $3.07 |
-11%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| LU |
A
|
Alvotech SA
NASDAQ:ALVO
|
1.1B USD | 27.5 | 38.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -2 855 158.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 23.4 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.1B USD | 20.7 | 22.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 24.2 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -480.6 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 33.9 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 19.9 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 159.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 35.5 | 29.5 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 8.4 |
| Median | 24.3 |
| 70th Percentile | 28.3 |
| Max | 2 151.7 |
Other Multiples
Alvotech SA
Glance View
In the fiercely competitive world of pharmaceuticals, Alvotech SA has carved out a distinct niche as a specialist in developing biosimilars—essentially highly similar alternatives to already approved biological medicines. Based in Iceland, the company was founded by Robert Wessman, renowned for his successful ventures in the pharmaceutical industry. Alvotech strives to not only make crucial medications more accessible but to also alleviate the strain of high drug costs on healthcare systems worldwide. With its ardent focus on quality and efficacy, Alvotech's innovative research and development strategies underline its commitment to replicating complex biologics, ensuring they are more affordable without compromising on safety and effectiveness. Alvotech’s business model is intricately woven into the fabric of collaboration and partnership. Rather than attempting to market its products independently, Alvotech aligns with a network of global partners for commercialization and distribution, allowing the company to reach diverse markets efficiently. This approach not only widens their reach but also minimizes the cost and time associated with entering new geographical territories. Alvotech generates revenue by selling these biosimilars, capitalizing on the expiration of patents on original biologic drugs. In doing so, it provides healthcare providers and patients with cost-effective options, positioning itself as a valuable player in the increasingly essential biosimilar market.
